Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

17 evidence topics · 15 sources

Warnings and precautions
Treatment-emergent and treatment-related adverse events: phase 1/2 monotherapy at 60 and 120 mg
Adverse event, n (%)60 mg, any grade (n = 30)120 mg, any grade (n = 86)120 mg, grade 3120 mg, grade 4
TEAE: nausea“14 (46.7)”View highlighted excerpt for this quote“54 (62.8)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: vomiting“5 (16.7)”View highlighted excerpt for this quote“25 (29.1)”View highlighted excerpt for this quote“4 (4.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: fatigue“13 (43.3)”View highlighted excerpt for this quote“22 (25.6)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: neutropenia“2 (6.7)”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“6 (7.0)”View highlighted excerpt for this quote
TEAE: headache“7 (23.3)”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: constipation“6 (20.0)”View highlighted excerpt for this quote“15 (17.4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAE: diarrhea“6 (20.0)”View highlighted excerpt for this quote“12 (14.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: nausea“10 (33.3)”View highlighted excerpt for this quote“47 (54.7)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: vomiting“3 (10.0)”View highlighted excerpt for this quote“21 (24.4)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: fatigue“9 (30.0)”View highlighted excerpt for this quote“17 (19.8)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TRAE: neutropenia“0”View highlighted excerpt for this quote“18 (20.9)”View highlighted excerpt for this quote“3 (3.5)”View highlighted excerpt for this quote“5 (5.8)”View highlighted excerpt for this quote
Neutropenia: phase 1/2 monotherapy

“Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Neutropenia, albeit at a lower frequency, has also been reported with fulvestrant, with grade ≥ 3 neutropenia observed in 1% to 2% of patients receiving fulvestrant monotherapy and rates of febrile neutropenia of 0 to 1% [30, 31].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Adverse events including neutropenia: combination with ribociclib
Related TEAE, n (%)120 mg + ribociclib, all grades (n = 56)120 mg, grade 3120 mg, grade 490 mg + ribociclib, all grades (n = 16)90 mg, grade 390 mg, grade 4
Neutropenia“47 (84%)”“28 (50%)”“5 (9%)”“13 (81%)”“9 (56%)”“2 (16%)”
WBC decrease“24 (43%)”“9 (16%)”“1 (2%)”“6 (38%)”“4 (25%)”“0”
Nausea“41 (73%)”“2 (4%)”“0”“11 (69%)”“1 (6%)”“0”
Fatigue“30 (54%)”“3 (5%)”“0”“9 (50%)”“0”“0”
Diarrhea“24 (43%)”“2 (4%)”“0”“4 (25%)”“0”“0”
Vomiting“21 (38%)”“1 (2%)”“0”“4 (25%)”“0”“0”
Electrocardiogram QT prolonged“16 (29%)”“4 (5%)”“0”“4 (25%)”“1 (6%)”“0”
AST increased“15 (27%)”“2 (4%)”“0”“3 (19%)”“0”“0”